Brokers Set Expectations for United Therapeutics Co.'s FY2024 Earnings (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Research analysts at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for shares of United Therapeutics in a research report issued to clients and investors on Wednesday, April 17th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will post earnings per share of $25.91 for the year, down from their prior estimate of $25.95. Leerink Partnrs has a "Outperform" rating on the stock. The consensus estimate for United Therapeutics' current full-year earnings is $23.46 per share. Leerink Partnrs also issued estimates for United Therapeutics' Q4 2024 earnings at $6.67 EPS and FY2025 earnings at $26.98 EPS.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping analysts' consensus estimates of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The firm had revenue of $614.70 million for the quarter, compared to analysts' expectations of $575.01 million. During the same quarter last year, the business posted $2.67 EPS. United Therapeutics's revenue was up 25.1% on a year-over-year basis.

UTHR has been the subject of a number of other reports. Wells Fargo & Company raised their price objective on United Therapeutics from $309.00 to $325.00 and gave the stock an "overweight" rating in a research report on Thursday, March 7th. SVB Leerink began coverage on United Therapeutics in a research report on Monday, February 5th. They set an "outperform" rating and a $330.00 price objective for the company. The Goldman Sachs Group upgraded United Therapeutics from a "sell" rating to a "neutral" rating and raised their price objective for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. Wedbush reiterated an "outperform" rating and set a $308.00 price target on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, April 11th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $292.67.

United Therapeutics Stock Up 0.4 %

NASDAQ UTHR traded up $1.00 during trading on Friday, reaching $237.93. 395,447 shares of the company's stock were exchanged, compared to its average volume of 434,215. United Therapeutics has a fifty-two week low of $204.44 and a fifty-two week high of $261.54. The firm has a market capitalization of $11.20 billion, a PE ratio of 11.99 and a beta of 0.52. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. The company's fifty day simple moving average is $231.71 and its 200-day simple moving average is $228.55.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business's stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $237.91, for a total value of $856,476.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,928.30. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of United Therapeutics stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company's stock, valued at approximately $30,756.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $237.91, for a total value of $856,476.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $30,928.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 129,790 shares of company stock worth $30,528,633. 12.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. First Trust Direct Indexing L.P. increased its position in United Therapeutics by 38.0% in the 1st quarter. First Trust Direct Indexing L.P. now owns 2,107 shares of the biotechnology company's stock worth $484,000 after buying an additional 580 shares during the period. State of Alaska Department of Revenue increased its position in shares of United Therapeutics by 153.5% during the first quarter. State of Alaska Department of Revenue now owns 16,557 shares of the biotechnology company's stock valued at $3,802,000 after purchasing an additional 10,025 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of United Therapeutics by 0.3% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 101,042 shares of the biotechnology company's stock valued at $23,211,000 after purchasing an additional 338 shares during the period. MBM Wealth Consultants LLC increased its position in shares of United Therapeutics by 2.7% during the first quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company's stock valued at $515,000 after purchasing an additional 59 shares during the period. Finally, State of Michigan Retirement System increased its position in shares of United Therapeutics by 2.5% during the first quarter. State of Michigan Retirement System now owns 12,232 shares of the biotechnology company's stock valued at $2,810,000 after purchasing an additional 300 shares during the period. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.